Transforming Tubulin Therapy For Brain Diseases

ABOUT REGLAGENE

Novel Therapeutics Are Lacking for Brain Cancer and Brain Diseases
Reglagene's lead program is a novel, orally administered, well-tolerated, blood–brain barrier penetrant therapy for the treatment of brain cancers.
Reglagene's product pipeline also includes disease indications driven by brain inflammation.
Reglagene Is Developing Novel Therapies for Diseases with High Unmet Medical Need
Potent, Orally Available, Blood–Brain Barrier Penetrant Therapies Are Rapidly Moving through Preclinical Development

SAFETY FIRST

Current cancer therapies are highly toxic. Most therapies are given intravenously and cause many unwanted side effects. It is important to the Reglagene team to develop orally available, well-tolerated medicines for patients to use in the comfort of their own homes.

BLOOD–BRAIN BARRIER (BBB) PENETRANT

Only 2% of all marketable drugs can cross the BBB, a filter that prevents toxins and medicines from entering the brain. Reglagene’s brain cancer therapy crosses the BBB and has nearly the same concentration in peripheral blood as in the brain.

WELL-VALIDATED TARGET

Reglagene's first therapy attacks a highly validated cancer target, previously inaccessible in brain cancer owing to the BBB. Many therapies and drug-delivery systems have tried and failed to access this target in brain. Reglagene has found a way to make this possible.

MEDICINES FOR A GLOBAL MARKET

Reglagene accesses the advantages of what are known as small-molecule medicines. Benefits of small molecule medicines include: oral administration, low manufacturing costs, and well-traveled development and regulatory pathways.

Reglagene Pipeline

Reglagene is Transforming Tubulin Therapies for brain Diseases by discovering and developing novel therapies

LEARN MORE

CONTACT REGLAGENE

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614

DONATE

Our Case For Change

EBCI In The News

Patient Support Services

Patient Resource Center

VOLUNTEER WITH EBCI

GET IN TOUCH

corporate partners

upcoming events

resources

About us